Xilio Therapeutics Statistics
Total Valuation
XLO has a market cap or net worth of $32.85 million. The enterprise value is $5.05 million.
| Market Cap | 32.85M |
| Enterprise Value | 5.05M |
Important Dates
The next estimated earnings date is Monday, August 12, 2024, before market open.
| Earnings Date | Aug 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
XLO has 36.91 million shares outstanding. The number of shares has increased by 1.75% in one year.
| Shares Outstanding | 36.91M |
| Shares Change (YoY) | +1.75% |
| Shares Change (QoQ) | +1.29% |
| Owned by Insiders (%) | 25.79% |
| Owned by Institutions (%) | 36.51% |
| Float | 21.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.28 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.19, with a Debt / Equity ratio of 0.35.
| Current Ratio | 2.19 |
| Quick Ratio | 2.11 |
| Debt / Equity | 0.35 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -155.60% and return on invested capital (ROIC) is -210.59%.
| Return on Equity (ROE) | -155.60% |
| Return on Assets (ROA) | -90.50% |
| Return on Capital (ROIC) | -210.59% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.27M |
| Employee Count | 56 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -66.84% in the last 52 weeks. The beta is -0.04, so XLO's price volatility has been lower than the market average.
| Beta (5Y) | -0.04 |
| 52-Week Price Change | -66.84% |
| 50-Day Moving Average | 1.06 |
| 200-Day Moving Average | 1.14 |
| Relative Strength Index (RSI) | 39.07 |
| Average Volume (20 Days) | 499,373 |
Short Selling Information
The latest short interest is 74,969, so 0.20% of the outstanding shares have been sold short.
| Short Interest | 74,969 |
| Short Previous Month | 445,015 |
| Short % of Shares Out | 0.20% |
| Short % of Float | 0.35% |
| Short Ratio (days to cover) | 0.16 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -73.09M |
| Pretax Income | -70.96M |
| Net Income | -70.96M |
| EBITDA | -69.12M |
| EBIT | -70.96M |
| Earnings Per Share (EPS) | -$2.57 |
Balance Sheet
The company has $36.74 million in cash and $8.94 million in debt, giving a net cash position of $27.80 million or $0.75 per share.
| Cash & Cash Equivalents | 36.74M |
| Total Debt | 8.94M |
| Net Cash | 27.80M |
| Net Cash Per Share | $0.75 |
| Equity (Book Value) | 25.77M |
| Book Value Per Share | 0.70 |
| Working Capital | 37.60M |
Cash Flow
In the last 12 months, operating cash flow was -$53.87 million and capital expenditures -$316,000, giving a free cash flow of -$54.19 million.
| Operating Cash Flow | -53.87M |
| Capital Expenditures | -316,000 |
| Free Cash Flow | -54.19M |
| FCF Per Share | -$1.94 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
XLO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.75% |
| Shareholder Yield | -1.75% |
| Earnings Yield | -216.00% |
| FCF Yield | -164.95% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -29.48% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |